BYSI News and Press, BeyondSpring Inc. From 05/24/21

- Data from U.S. Phase 1 dose escalation investigator-initiated trial demonstrated favorable safety and tolerability. - Plinabulin, in combination with nivolumab and ipilimumab, shows 46% objective response rate (ORR) in 13 evaluable patients with PD-1/PD-L1 naïve or resistan...

NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that that CEO Dr. Lan Huang is scheduled to present at the Bank of Am...

BeyondSpring Inc. (BYSI) Q4 2020 Results Conference Call April 30, 2021 08:30 AM ET Company Participants Andrew Ericsson - Investor Relations Dr. Lan Huang - Co-Founder, Chairwoman and Chief Executive Officer Dr. Ramon Mohanlal - EVP, Research and Development and Chief Medical Officer Richard...

Image source: The Motley Fool. BeyondSpring Inc. (NASDAQ: BYSI) Q1 2021 Earnings Call Apr 30, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: BeyondSpring Inc. (BYSI) Q1 2021 Earnings Call Transcript

The following slide deck was published by BeyondSpring Inc. in conjunction with their 2020 Q4 earnings call. For further details see: BeyondSpring Inc. 2020 Q4 - Results - Earnings Call Presentation

NEW YORK, April 30, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed its annual report on F...

BeyondSpring (BYSI): FY GAAP EPS of -$2.03 misses by $0.17.Revenue of $180K.CEO comment: “The Company is well positioned for the future, with our “pipeline in a drug” plinabulin, and anticipated near-term potential anti-cancer efficacy data from a Phase 3 trial measuring ...

- NDAs filed in the U.S. and China in Mar. 2021 based on superior data from Phase 3 PROTECTIVE-2 trial of Breakthrough Therapy Designation regimen, plinabulin plus G-CSF vs. G-CSF alone in prevention of CIN - Company subsidiary, SEED Therapeutics, signed an $...

- Four presentations to focus on the clinically meaningful endpoint improvement, including the reduction of febrile neutropenia and hospitalization, shown by plinabulin in the prevention of chemotherapy-induced neutropenia (CIN) - An additional presentation to focus on plinabuli...

NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will report its financial re...